Ernest C. Borden
#88,248
Most Influential Person Now
Ernest C. Borden's AcademicInfluence.com Rankings
Ernest C. Bordenmedical Degrees
Medical
#898
World Rank
#1159
Historical Rank
Oncology
#27
World Rank
#28
Historical Rank
Ernest C. Bordenphilosophy Degrees
Philosophy
#3183
World Rank
#5209
Historical Rank
Logic
#999
World Rank
#1614
Historical Rank
Download Badge
Medical Philosophy
Ernest C. Borden's Degrees
- Doctorate Medicine Johns Hopkins University
Why Is Ernest C. Borden Influential?
(Suggest an Edit or Addition)Ernest C. Borden's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684 (2023) (2027)
- Interferons at age 50: past, current and future impact on biomedicine (2007) (1093)
- Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. (2008) (942)
- Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis (2003) (811)
- Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer (2006) (751)
- Soft tissue sarcomas of adults: state of the translational science. (2003) (559)
- Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. (2008) (559)
- Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. (1998) (518)
- Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. (1987) (509)
- Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands (2010) (395)
- Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis (2004) (358)
- Immunoregulatory properties of ISG15, an interferon-induced cytokine. (1996) (327)
- Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. (2011) (303)
- Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. (1987) (259)
- Human polyomavirus infections with JC virus and BK virus in renal transplant patients. (1980) (229)
- In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. (1996) (228)
- Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. (2007) (219)
- High-throughput Immunoblotting (2003) (218)
- Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. (2005) (217)
- Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Physiocochemical and serological studies. (1971) (209)
- Preferential Induction of Apoptosis by Interferon (IFN)-β Compared with IFN-α2 (2001) (207)
- Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. (1996) (196)
- Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. (1992) (196)
- Depression of interferon production after A.L.S. treatment. (1969) (192)
- Comparative Antiproliferative Activity in Vitro of Natural Interferons α and β for Diploid and Transformed Human Cells (1982) (190)
- Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. (1991) (178)
- Interferons and their stimulated genes in the tumor microenvironment. (2014) (172)
- Induction of Tryptophan Degradation In Vitro and In Vivo: A γ-Interferon-Stimulated Activity (1986) (171)
- Meta-analysis to evaluate the role of interferon in follicular lymphoma. (2005) (171)
- Identification of X-linked Inhibitor of Apoptosis-associated Factor-1 as an Interferon-stimulated Gene That Augments TRAIL Apo2L-induced Apoptosis* (2002) (168)
- Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon. (1979) (167)
- A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. (1991) (165)
- Interferon‐lnduced Indoleamine 2,3‐Dioxygenase Activity in Human Mononuclear Phagocytes (1989) (161)
- Interferons α and β in cancer: therapeutic opportunities from new insights (2019) (159)
- Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. (1987) (155)
- Defining the critical hurdles in cancer immunotherapy (2011) (152)
- Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. (1989) (148)
- An overview of the interferon system: signal transduction and mechanisms of action. (1996) (140)
- Further clinical studies with intrahepatic arterial infusion with 5‐fluorouracil (1975) (140)
- Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. (1982) (132)
- Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. (2006) (131)
- Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033. (2004) (130)
- Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. (2002) (125)
- Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies. (1971) (124)
- Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. (1989) (124)
- Modulation of Interferon (IFN)-inducible Gene Expression by Retinoic Acid (1996) (117)
- Lymphokines and cytokines as cancer treatment.Immunotherapy realized (1990) (116)
- Concepts of fever: recent advances and lingering dogma. (1997) (116)
- Interferons: biochemical, cell growth inhibitory, and immunological effects. (1981) (114)
- Malignant mesothelioma. The eastern cooperative oncology group (ECOG) experience (1983) (111)
- Novel Growth and Death Related Interferon-Stimulated Genes (ISGs) in Melanoma: Greater Potency of IFN-β Compared with IFN-α2 (2003) (110)
- Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. (1984) (106)
- Phase 2 Southwest Oncology Group‐directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas (2012) (102)
- Emerging roles of FAM14 family members (G1P3/ISG 6-16 and ISG12/IFI27) in innate immunity and cancer. (2011) (98)
- Treatment of multiple myeloma with recombinant alpha-interferon (1986) (97)
- Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. (1989) (97)
- A perspective on the clinical effectiveness and tolerance of interferon-alpha. (1998) (95)
- Second-generation interferons for cancer: clinical targets. (2000) (95)
- Suppression of NF-κB Survival Signaling by Nitrosylcobalamin Sensitizes Neoplasms to the Anti-tumor Effects of Apo2L/TRAIL* (2003) (93)
- Interferon stimulated gene 15 constitutively produced by melanoma cells induces e-cadherin expression on human dendritic cells. (2002) (92)
- Low doses of interferon alpha result in more effective clinical natural killer cell activation. (1985) (90)
- Retinoic acid and interferon in human cancer: mechanistic and clinical studies. (1994) (89)
- G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. (2007) (89)
- Interferons and indoleamine 2,3-dioxygenase: Role in antimicrobial and antitumor effects (1989) (88)
- A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors (2009) (87)
- Interferons: rationale for clinical trials in neoplastic disease. (1979) (86)
- Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). (2006) (85)
- Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. (1996) (85)
- Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. (1997) (84)
- Prognostic factors in metastatic melanoma (1993) (84)
- IFN-β Pretreatment Sensitizes Human Melanoma Cells to TRAIL/Apo2 Ligand-Induced Apoptosis1 (2002) (82)
- Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. (1993) (81)
- Combinations of DNA Methyltransferase and Histone Deacetylase Inhibitors Induce DNA Damage in Small Cell Lung Cancer Cells: Correlation of Resistance with IFN-Stimulated Gene Expression (2010) (80)
- Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2. (2003) (79)
- Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. (1986) (79)
- Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer (2006) (79)
- Beta interferon inhibits Toxoplasma gondii growth in human monocyte-derived macrophages (1989) (78)
- Interleukin-6: a cytokine with potential diagnostic and therapeutic roles. (1994) (77)
- Enhancement of T cell cytotoxic responses by purified human fibroblast interferon. (1978) (77)
- Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. (1992) (77)
- Synergistic Antiproliferative Effects of Human Recombinant α54- or βser-Interferon with γ-Interferon on Human Cell Lines of Various Histogenesis (1986) (77)
- Effect of influenza A virus on leukocyte histamine release. (1983) (75)
- Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. (1987) (75)
- Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033 (2017) (74)
- Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine. (1989) (74)
- Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. (1996) (72)
- Rapid detection and identification of JC virus and BK virus in human urine by using immunofluorescence microscopy (1980) (69)
- Progress toward therapeutic application of interferons, 1979–1983 (1984) (69)
- Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL (2008) (67)
- Estrogen and Progesterone Receptor Expression in Uterine and Extrauterine Leiomyosarcomas: An Immunohistochemical Study (2004) (67)
- Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. (1984) (66)
- Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft‐tissue sarcomas (1990) (66)
- A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors (2005) (64)
- Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. (2006) (63)
- Anticancer Activity of Sodium Stibogluconate in Synergy with IFNs1 (2002) (63)
- Phase I evaluation of a synthetic mutant of β-interferon (1985) (63)
- Natural Soluble Interleukin-15Rα Is Generated by Cleavage That Involves the Tumor Necrosis Factor-α-converting Enzyme (TACE/ADAM17)* (2004) (63)
- Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). (2008) (62)
- Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta. (1993) (62)
- Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. (1997) (61)
- Retinoic acid-inducible gene-I is induced by interferon-γ and regulates the expression of interferon-γ stimulated gene 15 in MCF-7 cells (2004) (60)
- Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 (2020) (60)
- Growth Inhibitory Effects of Interferon-β but Not Interferon-α on Human Glioma Cells: Correlation of Receptor Binding, 2′,5′-O1igoadenylate Synthetase and Protein Kinase Activity (1990) (60)
- Melanoma and pregnancy. (2000) (57)
- Novel SHP-1 Inhibitors Tyrosine Phosphatase Inhibitor-1 and Analogs with Preclinical Anti-Tumor Activities as Tolerated Oral Agents (2010) (56)
- Pharmacokinetics and Tolerability of an Antiangiogenic Ribozyme (ANGIOZYME™) in Healthy Volunteers (2000) (55)
- Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon. (1987) (54)
- Interferon-stimulated genes and their protein products: what and how? (2011) (54)
- Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The eastern cooperative oncology group (ECOG) experience (1989) (54)
- G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer (2012) (51)
- A Notch1–neuregulin1 autocrine signaling loop contributes to melanoma growth (2012) (51)
- Effects of cytokines on the pituitary-adrenal axis in cancer patients. (1993) (50)
- Measurement of 2',5'-oligoadenylate synthetase in patients receiving interferon-alpha. (1985) (49)
- Radiosensitization of human bronchogenic carcinoma cells by interferon beta. (1984) (49)
- Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro. (1997) (49)
- Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser. (1989) (49)
- The effect of interferon on the metabolism of LDLs. (1992) (48)
- Interferons--expanding therapeutic roles. (1992) (48)
- Phase II trial of interferon-β for treatment of recurrent glioblastoma multiforme (1986) (45)
- Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen. (1989) (44)
- Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17). (2004) (44)
- Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505 (2008) (43)
- Review: Milstein Award lecture: interferons and cancer: where from here? (2005) (43)
- Antiproliferative effects of interferons on human melanoma cells in the human tumor colony-forming assay. (1986) (42)
- Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis. (2013) (42)
- Interferons: pleiotropic cellular modulators. (1992) (42)
- Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. (1982) (41)
- Endoscopic and open surgical approaches to locally advanced sinonasal melanoma: comparing the therapeutic benefits. (2014) (41)
- Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity. (1984) (41)
- Absence of Biological Effects of Orally Administered Interferon-βser (1992) (40)
- Reverse Signaling through Membrane-bound Interleukin-15* (2004) (39)
- Augmented antiproliferative effects of interferons at elevated temperatures against human bladder carcinoma cell lines. (1984) (39)
- Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons. (1991) (39)
- Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma (2011) (39)
- Phase II Trial of Gemcitabine as First Line Chemotherapy in Patients With Metastatic or Unresectable Soft Tissue Sarcoma (2006) (38)
- Isoforms p69 and p100 of 2',5'-oligoadenylate synthetase induced differentially by interferons in vivo and in vitro. (1993) (38)
- Decreases in serum high-density-lipoprotein cholesterol and total cholesterol resulting from naturally produced and recombinant DNA-derived leukocyte interferons. (1984) (38)
- Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro. (2008) (38)
- Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans. (1984) (37)
- Phase I trial of human lymphoblastoid interferon with whole body hyperthermia in advanced cancer. (1989) (36)
- Streptovaricins inhibit focus formation by MSV (MLV) complex. (1971) (35)
- Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon. (1998) (35)
- Plasma lipoprotein changes in humans induced by β-interferon (1987) (35)
- Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686) (2003) (35)
- Retinoic acid-inducible gene-I is induced by interferon-gamma and regulates the expression of interferon-gamma stimulated gene 15 in MCF-7 cells. (2004) (35)
- The interferon refractory state: in vivo and in vitro studies of its mechanism. (1971) (34)
- Aquanititave semimicro, semiautomated colorimetric assay for interferon. (1977) (34)
- Clinical and biological effects of recombinant interferon-beta administered intravenously daily in phase I trial. (1988) (34)
- Effects of recombinant interferon-alpha 2 treatment upon lipid concentrations and lipoprotein composition. (1986) (33)
- Tamoxifen enhances interferon-regulated gene expression in breast cancer cells (1997) (32)
- Augmented Tumor-Associated Antigen Expression by Interferons1 (1988) (32)
- IFN-α2b and thalidomide synergistically inhibit tumor-induced angiogenesis (2003) (31)
- Survey of human polyomavirus (JCV, BKV) infections in 139 patients with lung cancer, breast cancer, melanoma, or lymphoma. (1983) (31)
- Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas (1990) (31)
- Further clinical studies with megestrol acetate in advanced breast cancer (1976) (31)
- Differentiation therapy of cancer: laboratory and clinical investigations. (1993) (30)
- The appearance of hypodense eosinophils during interleukin-2 treatment. (1990) (30)
- Clinical and biologic effects of combination therapy with gamma‐interferon and tumor necrosis factor (1992) (29)
- Noncanonical Activation of Notch1 Protein by Membrane Type 1 Matrix Metalloproteinase (MT1-MMP) Controls Melanoma Cell Proliferation* (2014) (29)
- Effects of Interferon βser and Transforming Growth Factor β on Prostatic Cell Lines (1991) (29)
- Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects (2011) (29)
- Treatment of multiple myeloma with recombinant alpha-interferon. (1986) (28)
- Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion. (1983) (28)
- Basal and interferon-induced 2',5'-oligoadenylate synthetase in human monocytes, lymphocytes, and peritoneal macrophages. (1990) (28)
- An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival (2013) (27)
- Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial. (2011) (27)
- A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. (1990) (27)
- American Cancer Society Phase I Trial of Naturally Produced β-Interferon (1984) (26)
- Hepatocellular Carcinoma: An ECOG Randomized Phase II Study of Beta‐Interferon and Menagoril (1995) (26)
- Selective inhibition by streptovaricin of splenomegaly induced Rauscher leukaemia by virus. (1971) (26)
- Binding of recombinant-produced interferon beta ser to human lymphoblastoid cells. Evidence for two binding domains. (1987) (25)
- New and modified interferon alfas: Preclinical and clinical data (2003) (25)
- An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma. (1985) (25)
- High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study. (1987) (24)
- Biological and Clinical Effects of the Combination of β- and γ-Interferons Administered as a 5-Day Continuous Infusion (1990) (24)
- Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity. (1990) (24)
- Biologic response modifiers as adjuncts to other therapeutic modalities. (1986) (24)
- Prevalence of Circulating Tumor Cells in Localized Prostate Cancer (2013) (24)
- Studies on the poxvirus Cotia. (1980) (24)
- Interferons: biological and clinical effects. (1989) (24)
- Methylthioadenosine phosphorylase gene deletions are frequently detected by fluorescence in situ hybridization in conventional chondrosarcomas. (2006) (24)
- Intimal pulmonary artery sarcoma presenting as dyspnea: case report (2007) (24)
- Phase II Trial of a Combination of Interferon-βser and Interferon-γ in Patients with Advanced Malignant Melanoma (1988) (23)
- Inhibitory effects of interferon-inducing pyrimidinones on the growth of transplantable mouse bladder tumors. (1986) (23)
- Tacaribe virus infection of the mouse: an immunopathologic disease model. (1974) (23)
- Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1). (2002) (23)
- Modulation of 2',5'-oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedule, and route of administration. (1986) (23)
- Reverse signaling through membrane-bound interleukin-15. (2011) (22)
- Innovative treatment strategies for non-Hodgkin's lymphoma and multiple myeloma. (1994) (22)
- IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis. (2003) (22)
- Dual regulation of Stat1 and Stat3 by the tumor suppressor protein PML contributes to interferon α-mediated inhibition of angiogenesis (2017) (21)
- Antiproliferative activity of human interferons against ovarian cancer cells grown in human tumor stem cell assay. (1984) (21)
- Current status of interferons in the treatment of cancer. (1992) (21)
- Effects of interferons in neoplastic diseases of man. (1988) (20)
- Preclinical and clinical studies of interferons and interferon inducers in breast cancer (1984) (20)
- Effects of thorotrast on humoral antibody, viral multiplication, and interferon during infection with St. Louis encephalitis virus in mice. (1971) (20)
- Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors (2007) (20)
- Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology Group. (1997) (20)
- Sodium Stibogluconate Interacts with IL-2 in Anti-Renca Tumor Action via a T Cell-Dependent Mechanism in Connection with Induction of Tumor-Infiltrating Macrophages1 (2005) (20)
- Re-inventing intratumoral immunotherapy for melanoma. (2011) (20)
- Production of ISG-15, an interferon-inducible protein, in human corneal cells. (1996) (20)
- Biological and Clinical Effects of Interferon-βser at Two Doses (1990) (19)
- Dual VEGF/VEGFR inhibition in advanced solid malignancies (2014) (19)
- Interferons: Biological Response Modification and Pharmacology (1982) (19)
- IFN-α1,8 inhibits tumor-induced angiogenesis in murine angiosarcomas (2006) (19)
- Clinical benefit of imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial (2005) (19)
- Inhibitory effects of cytokines on vascular endothelial cells: Synergistic interactions among interferon-γ, tumor necrosis factor-α, and interleukin-1 (1992) (18)
- The interferon refractory state. II. Biological characterization of a refractoriness-inducing protein. (1975) (18)
- Increasing effectiveness of interferon-alpha for malignancies. (1997) (17)
- Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma. (2007) (17)
- Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM). (2004) (17)
- IFN-alpha1,8 inhibits tumor-induced angiogenesis in murine angiosarcomas. (2006) (17)
- The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon (2012) (17)
- Phase 2 Trial of Interferon-Beta as Second-Line Treatment of Ovarian Cancer, Fallopian Tube Cancer, or Primary Carcinoma of the Peritoneum (2004) (17)
- Biological therapies for breast carcinoma: concepts for improvement in survival. (1999) (17)
- Phase II Trial of Carboplatin in Soft‐Tissue Sarcoma (1990) (17)
- Immunological Effects of Levamisole In Vitro (1991) (17)
- Interferons: Effectiveness, Toxicities, and Costs (1996) (17)
- Phase ii evaluation of a combination of mitomycin C, vincristine, and cisplatin in advanced non‐small cell lung cancer (1986) (17)
- Effects of diethyldithiocarbamate, an inhibitor of interferon antiviral activity, upon human natural killer cells. (1984) (16)
- Recombinant Human Interferon-β (rHuIFN-β) and Radiation Therapy for Inoperable Non-Small Cell Lung Cancer (1996) (16)
- Phase II evaluation of dibromodulcitol, ICRF‐159, and maytansine for sarcomas (1982) (16)
- Assessment of the antigenic response in humans to a recombinant mutant interferon beta (1987) (16)
- Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine. (1990) (16)
- 2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals. (1991) (16)
- Tyrosine Phosphatase Inhibitor-3 Sensitizes Melanoma and Colon Cancer to Biotherapeutics and Chemotherapeutics (2010) (16)
- Hematologic and immunologic evaluation of recombinant human interleukin-6 in patients with advanced malignant disease: evidence for monocyte activation. (1996) (16)
- A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an Eastern Cooperative Oncology Group study (PB687) (1998) (16)
- Natural soluble interleukin-15Rα is generated by cleavage that involves the tumor necrosis factor-α-converting enzyme (TACE/ADAM17). (2011) (15)
- Enhancement of rIn:rCn-Induced Interferon Production by Amphotericin B (1976) (15)
- Effects of Interferons β or γ on Neopterin Biosynthesis and Tryptophan Degradation by Human Alveolar Macrophages In Vitro: Synergy with Lipopolysaccharide (1992) (15)
- Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma (2014) (15)
- Plasma lipoprotein changes in humans induced by beta-interferon. (1987) (15)
- Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033. (2014) (15)
- Requirement of differentiative signals of both interferon-gamma and 1,25-dihydroxyvitamin D3 for induction and secretion of interleukin-1 by HL-60 cells. (1988) (15)
- Interferons as biochemical modulators. (1996) (15)
- Personalizing medicine for cancer: the next decade (2010) (15)
- Enhancement of indoleamine 2,3-dioxygenase activity in cancer patients receiving interferon-beta Ser. (1989) (15)
- EFFECTS OF INTERFERONS AND INTERLEUKIN-2 ON TRYPTOPHAN METABOLISM IN HUMANS (1987) (14)
- Induced proteins in human peripheral mononuclear cells over a range of clinically tolerable doses of interferon-gamma. (1989) (14)
- Effects of interleukin-2 (IL-2) on human plasma lipid, lipoprotein, and C-reactive protein (1990) (13)
- Mechanistic Studies of Polyene Enhancement of Interferon Production by Polyriboinosinic-Polyribocytidylic Acid (1978) (13)
- Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo. (2009) (13)
- Phase I Dose-Escalation Study of VB-111, an Antiangiogenic Virotherapy, in Patients with Advanced Solid Tumors (2013) (13)
- Antitumor effects of polyribonucleotides for mouse transitional cell carcinoma enhanced by cyclophosphamide. (1985) (13)
- Effect of Antilymphocyte Serium on Tacaribe Virus Infection in Infant Mice (1971) (13)
- Epirubicin has modest single-agent activity in head and neck cancer but limited activity in metastatic melanoma and colorectal cancer: phase II studies by the Eastern Cooperative Oncology Group. (1998) (13)
- Incidence and reasons for dose modification of standard-dose vs. high-dose imatinib mesylate (IM) in the Phase III Intergroup Study S0033 of patients (pts) with unresectable or metastatic gastrointestinal stromal tumor (GIST) (2005) (13)
- Phase I trial of combinations of recombinant interferons beta(ser) and gamma in patients with advanced malignancy. (1987) (12)
- Biologic Activity of Polyethylene Glycol12000–Interferon-&agr;2b Compared with Interferon-&agr;2b: Gene Modulatory and Antigrowth Effects in Tumor Cells (2003) (12)
- Comparative Pharmacokinetics and Pharmacodynamics of Two Recombinant Human Interferon Beta la (IFNβ-1a) Products Administered Intramuscularly in Healthy Male and Female Volunteers (2004) (12)
- Malignant melanoma: treatments emerging, but early detection is still key. (2002) (12)
- Gene Modulatory Effects, Pharmacokinetics, and Clinical Tolerance of Interferon‐α1b: A Second Member of the Interferon‐α Family (2007) (12)
- Hypertrophic Osteoarthropathy and Pregnancy (1969) (12)
- Melanoma : biologically targeted therapeutics (2002) (12)
- Inhibition of hormone-dependent and independent breast cancer cell growthin vivo andin vitro with the antiestrogen toremifene and recombinant human interferon-α2 (1990) (12)
- Interferons: from virus inhibitor to modulator of amino acid and lipid metabolism. (1987) (11)
- Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta. (1988) (11)
- Phase II trial of acivicin in malignant mesothelioma. (1987) (11)
- Efficacy of SSG and SSG/IFNα2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action (2007) (11)
- Effects of Amphotericin B and Its Methyl Ester on the Antiviral Activity of Polyinosinic:Polycytidylic Acid (1979) (11)
- Biological Properties of Recombinant  «-Interfà © rons : 40 th Anniversary of the Discovery of Interferons 1 (2006) (11)
- Accumulation of guanylate binding proteins in patients treated with interferons. (1988) (11)
- Priming of human alveolar macrophages and blood monocytes for superoxide anion release by interferons and lipopolysaccharide. (1991) (11)
- Response and resistance to interferons and interacting cytokines. (1995) (11)
- Applications of monoclonal antibodies and recombinant cytokines for the treatment of human colorectal and other carcinomas (1991) (11)
- Recovery from massive amitriptyline overdosage. (1968) (11)
- Modulation of Interferon Receptor Expression during Combination βser-Interferon and γ-Interferon Treatment of Human Colon Carcinoma Cells (1990) (10)
- Augmented tumor-associated antigen expression by interferons. (1988) (10)
- Interferons and cancer: how the promise is being kept. (1983) (10)
- Phase II trial of a combination of interferon-beta ser and interferon-gamma in patients with advanced malignant melanoma. (1988) (9)
- Interferon-alpha-n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma. (1990) (9)
- VB-111 for cancer (2011) (9)
- Effects of interferon beta ser and transforming growth factor beta on prostatic cell lines. (1991) (9)
- Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects. (2003) (9)
- Comparison of agar and agarose preparations for mengovirus plaque formation. (1970) (9)
- A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer. (1993) (9)
- Effect of interferon alpha, interferon beta, and interferon gamma on the in vitro growth of human renal adenocarcinoma cells (2004) (8)
- A phase II study of dihydroxyanthracenedione (DHAD, Mitoxantrone, NSC 301739) in advanced malignant melanoma (2004) (8)
- Enhancement of infectivity of encephalomyocarditis virus RNA by amphotericin B methyl ester. (1979) (8)
- Hexamethylmelamine treatment of sarcomas and lymphomas. (1977) (8)
- Apoptosis: a clinical perspective (2008) (8)
- Divergence in activation by poly I:C of human natural killer and killer cells (2004) (8)
- Treatment of Multiple Myeloma With Recombinant a-Interferon (2005) (8)
- Increase by calcium in production of interferon by L929 cells induced with polyriboinosinate-polyribocytidylate complex. (1978) (8)
- Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family. (2007) (7)
- Correlation between in vitro and systemic effects of native and recombinant interferons-alpha on human natural killer cell cytotoxicity. (1983) (7)
- Phase I trials of targeted anticancer drugs: a need to refocus (2012) (7)
- Effects of interferons beta or gamma on neopterin biosynthesis and tryptophan degradation by human alveolar macrophages in vitro: synergy with lipopolysaccharide. (1992) (7)
- American cancer society Phase I trial of naturally produced beta-interferon. (1984) (7)
- In vitro and in vivo effects of levamisole on monocyte chemotaxis in normal donors and patients with colorectal carcinoma. (1983) (6)
- Levamisole and 5-fluorouracil in metastatic colorectal carcinoma (1982) (6)
- Human recombinant interferon-βSER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse (2004) (6)
- Circulating tumor cells versus imaging : Predicting overall survival in metastatic breast cancer. Commentary (2006) (6)
- Molecular diagnosis and monitoring of leukemia and lymphoma. (1993) (6)
- Recombinant interferon-gamma preserves human granulocyte bactericidal and chemoluminescence activities. (1993) (6)
- Phase II Trials of Interferons-α and -β in Advanced Sarcomas (1992) (6)
- Absence of biological effects of orally administered interferon-beta ser. (1992) (6)
- Variation in the binding of 125I-labeled interferon-beta ser to cellular receptors during growth of human renal and bladder carcinoma cells in vitro. (1987) (6)
- Reducing primary melanoma mortality (2000) (6)
- Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma (2004) (6)
- Phase II trial of interferon-beta for treatment of recurrent glioblastoma multiforme. (1986) (6)
- Biological and clinical effects of interferon-beta ser at two doses. (1990) (6)
- Synergistic antiproliferative effects of human recombinant alpha 54- or beta ser-interferon with gamma-interferon on human cell lines of various histogenesis. (1986) (6)
- Modulation of tumor-associated antigen expression on human pancreatic and prostate carcinoma cells in vitro by alpha- and gamma-interferons. (1995) (5)
- Effects of levamisole on human natural killer and killer cell activity and production of interferons. (1982) (5)
- Enhancement in recall antigen responses by frequent, repetitive skin testing with candida, mumps, and streptokinase-streptodornase in 38 normal adults (1980) (5)
- Interferons: Preclinical Rationale for Trials in Human Bladder Carcinoma (1982) (5)
- Interferon type I and II antagonism: a novel regulatory mechanism of indoleamine dioxygenase induction in human peripheral blood monocytes and peritoneal macrophages. (1991) (5)
- Effects of combinations of interferon-beta ser and interferon-gamma on interferon-inducible proteins and on the cell cycle. (1990) (5)
- Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion. (1990) (5)
- Immunologic function during adjuvant BCG immunotherapy for malignant melanoma: Induction of anergy (1979) (5)
- 9404 ORAL Long-term Survival on S0033 – a Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate at Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumours (GISTs) (2011) (5)
- Molecular characterization of soft tissue tumors (2002) (5)
- SELECTIVE INHIBITION OF VIRAL FUNCTIONS: THE ANTIVIRAL ACTION OF INTERFERON AND STREPTOVARICIN (1972) (5)
- A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin. (1989) (4)
- Phase I/IB study of polyadenylic-polyuridylic acid in patients with advanced malignancies: clinical and biologic effects. (1996) (4)
- Influence of non-specific immunologic factors on prognosis in advanced bronchogenic carcinoma (2004) (4)
- Antiproliferative effects of recombinant interferons alpha, beta, and gamma on renal carcinoma cells (1984) (4)
- Inhibitory effects of cytokines on vascular endothelial cells: synergistic interactions among interferon-gamma, tumor necrosis factor-alpha, and interleukin-1. (1992) (4)
- Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer. (1996) (4)
- Antiproliferative and Clinical Antitumor Effects of Interferons (1988) (4)
- Effects of interferon alpha on the sheep erythrocyte "receptor" of human lymphocytes. (1984) (4)
- Melanoma 2007: current state and preview of the future. (2007) (4)
- Phase I and pharmacokinetic study of sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] / indazolehydrochloride (1:1.1) (FFC14A, KP1019) in patients with solid tumors - a study of the CESAR Central European Society for Anticancer Drug Research - EWIV. (2005) (4)
- Epigenetic regulation of IFN-{alpha}2b in multiple myeloma by a hydroxamic acid histone deacetylase (HDAC) inhibitor (SAHA) and a non-hydroxamic acid HDAC inhibitor (A-423378) (2007) (4)
- Biological and clinical effects of the oral immunomodulator 3,6-bis(2-piperidinoethoxy)acridine trihydrochloride in patients with malignancy. (1990) (4)
- Interferons: Current status and future directions of this prototypic biological (2004) (4)
- 2-5A synthetase activity in patients with metastatic carcinoma and its response to interferon treatment. (1985) (3)
- Williamsburg Conference on Biological and Immunological Treatments for Cancer, 1992. (1993) (3)
- Potential role of polyribonucleotides in human neoplastic diseases. (1985) (3)
- Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma (2004) (3)
- Abstract 1361: A Phase I trial of VB-111, a tissue and condition specific vascular disruptive anti-angiogenic agent, based on novel Vascular Targeting System™, VTS™, for treatment of patients with advanced metastatic cancer (2010) (3)
- Modulation of 2',5'-oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedule, and route of administration. (1986) (3)
- Synergistic cytotoxicity for L929 cells of polyriboinosinic-polyribocytidylic acid and amphotericin B methyl ester. (1978) (3)
- Abstract 2372: Capture and molecular characterization of CTC in metastatic breast, prostate, colorectal, and renal cancer (2012) (3)
- Phase II trials of interferons-alpha and -beta in advanced sarcomas. (1992) (3)
- Inhibition by streptovaricins of rauscher leukemia virus splenomegaly (1974) (2)
- Antiproliferative and radiosensitizing effects of interferons on human lung carcinoma cells (1981) (2)
- A phase II study of linsitinib (OSI-906) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). (2013) (2)
- Introduction: Seminars in Oncology (1998) (2)
- Adjuvant Chemotherapy for Stage II Rectal Cancer. (2015) (2)
- PHASE I EVALUATION OF HUMAN INTERFERON-α FOLLOWING INTRAARTERIAL, INTRATUMOR INFUSION–PHARMACOKINETIC AND IMMUNOLOGIC ANALYSIS (1982) (2)
- Modulation of Tumor‐Associated Antigen Expression on Human Pancreatic and Prostate Carcinoma Cells In Vitro by α- and γ‐Interferons (1995) (2)
- Whole body hyperthermia (wbh) in mice: a simple technique and its use in the treatment of akr leukemia. Abstr. (1982) (2)
- Modulation of interferon receptor expression during combination beta ser-interferon and gamma-interferon treatment of human colon carcinoma cells. (1990) (2)
- Tumor-and Lymphocyte-induced Vascular Responses Inhibition of Angiogenesis by Interferons : Effects on Updated Version (2006) (2)
- Interferons in the treatment of multiple myeloma. (1990) (2)
- Attempted Suppression of the Interferon Response in the Mouse (1970) (2)
- Macrophages with Induction of Tumor-Infiltrating Cell-Dependent Mechanism in Connection Anti-Renca Tumor Action via a T Sodium Stibogluconate Interacts with IL-2 in (2005) (2)
- Short communication: phase I clinical and gene modulatory evaluation of tamoxifen and IFN-alpha2b. (2006) (2)
- Dual mechanistic function of MDSC subsets in melanoma resistance. (2010) (2)
- Hypertrophic osteoarthropathy and pregnancy. (1970) (2)
- Biological and Clinical Properties of the Type 1 Interferons (2006) (2)
- VIRAL CHEMOTHERAPY: ITS PROMISE AND PROBLEMS (1972) (2)
- CirculatingTumor Cells versus ImagingPredicting Overall Survival in Metastatic Breast Cancer (2006) (2)
- Inhibition of the IGF pathway in metastatic castrate resistant prostate cancer (CRPC): Results from a phase II study of OSI-906 (linsitinib). (2013) (2)
- Antiproliferative activity of recombinant interferons alpha and beta for human renal carcinoma cells: Supra-additive activity with elevated temperature or vinblastine (1986) (2)
- Circulating tumor cell kinetics in mRCC patients treated with sunitinib (2014) (2)
- Modulation of in vitro growth kinetics of renal cell carcinoma treated with α- and β-interferon (1983) (2)
- Separation of human natural killer cell subpopulations differentially responsive to interferon potentiation. (1986) (2)
- The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon (2012) (1)
- Proangiogenic neutrophilic-myeloid-derived suppressor cells emerge via two parallel pathways in renal cell carcinoma and melanoma (2013) (1)
- Polyriboinosinic:polyribocytidylic acid (poly i:c) as an antitumor compound: factors influencing in vivo activity. Abstr. (1979) (1)
- Biotechnology products in cancer therapy: a colloquium. (1988) (1)
- Cellular modulation of induction by polyribonucleotides of interferons. (1981) (1)
- Reactivation of the tumor suppressor RASSF1A by selective depletion of DNA methyltransferase 1 (DNMT1) by MG98 sensitizes renal cancer cells to interferon (IFN)-induced apoptosis (2005) (1)
- Interferons in Combination with Cytotoxic Modalities for Cancer Treatment (1988) (1)
- Antitumor effects of interferons (IFNs) and two IFN-inducing pyrimidinones (1985) (1)
- Abstract #5551: The impact of expression of BER proteins on therapeutic effect of combining temozolomide with methoxyamine in melanoma cells (2009) (1)
- Chemoprophylaxis by Interferons or Inducers against Chemical Carcinogenesis (1987) (1)
- Phase IA/IB Evaluation of Mammalian Cell‐derived Glycosylated Recombinant Human Interleukin (SIGOSIX) before and after Cytotoxic Chemotherapy (1995) (1)
- Separation of Human Natural Killer Cell (1986) (1)
- Book Review The Story of Interferon: The ups and downs in the life of a scientist By K. Cantell. 239 pp., illustrated. River Edge, N.J., World Scientific, 1998. $22. 981-02-3148-2 (1999) (1)
- Detection of circulating tumor cells in advanced renal cell carcinoma patients using microfilter-based capture (2012) (1)
- Comparison of Agar and Agarose Preparations for Mengovirus Plaque Formation (1970) (1)
- P061 SHP-1 inhibitors to enhance signaling and IFN-Γ production by activated T cells, mediate antitumor effects of through IFN-g, and to augment blockade of CTLA-4 by ipilimumab (2012) (1)
- Phase I trial of docetaxel, carboplatin and lenalidomide in patients with advanced solid tumors. (2006) (1)
- Abstract #5547: Enhancement of decitabine cytotoxicity by methoxyamine via inhibition of base excision repair (2009) (1)
- Abstract 2013: Interferon gamma receptor 2 (IFNgR2) has a ligand (IFNg)-independent activity as a Bax inhibitor in cancer cells (2012) (1)
- Withdrawal: Suppression of NF-κB survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. (2019) (1)
- American cancer society phase I trial of human interferon beta (IFN-β) (1982) (1)
- Transcriptional induction of genes by IFN-beta in mouse cells is regulated by a transcription factor similar to human ISGF-3. (1994) (1)
- MECHANISMS OF TUMOR PREVENTION BY INTERFERON ?? AND TAMOXIFEN: INHIBITORS OF ANGIOGENESIS (1993) (1)
- Book Review Cancer Immune Therapy: Current and Future Strategies Edited by Gernot Stuhler and Peter Walden. 408 pp., illustrated. Weinheim, Germany, Wiley-VCH, 2002. $160. 3-527-30441-X (2003) (1)
- Induction of TRAIL and XAF-1 and inhibition of p-Akt and c-Kit expression by interferons (IFNs) is associated with apoptosis in GIST cells (2004) (1)
- Phase II study of dibromodulcitol in colorectal, kidney, and other carcinomas. (1981) (1)
- Interferons and Interleukin-2: Molecular Basis of Activity and Therapeutic Results (2009) (1)
- INTERFERONS: UPDATE ON BIOLOGICAL AND CLINICAL ACTIVITIES (1993) (1)
- Lack of interferon production by dipyridamole. (1988) (1)
- 623 Gene expression enhancement by inhibitors of methylation: potential role in augmentation of apoptosis induced by interferons (IFNs) in melanoma and renal cell carcinoma (RCC) (2004) (1)
- Interferons: therapy for cancer (2009) (1)
- Side Effects of Interferon-α : Possible Clinical Causes and Intervention Strategies (1998) (0)
- Abrogation of ARA-C Cytotoxicity for Renal Carcinoma Cells with IFN Beta Serine (1987) (0)
- Interferons and polyribonucleotides for transplantable bladder carcinoma. Abstr. (1983) (0)
- Host Responses to Melanoma (2006) (0)
- Abstract 3336: The Smac Mimetic Birinapant Synergistically Induces Apoptosis in Combination with Type I Interferons and GM-CSF. (2013) (0)
- Specific high affinity binding of I-125 human interferon β to human cell receptors (1984) (0)
- Chapter 52 – Interferons (2008) (0)
- The Interferon Refractory State (1975) (0)
- Interferons and Their Induction (2021) (0)
- 335 SHP-1 protein tyrosine phosphatase as a target molecule in anti-tumor immune therapies: SHP-1 inhibitor SSG interacts withIL-2 to increase anti-murine renal tumor immunity (2004) (0)
- G1P3 (ISG 6-16), an interferon (IFN) stimulated survival factor antagonizes TRAIL/Apo2L induced apoptosis in myeloma cells (2007) (0)
- EVIDENCE THAT RECOMBINANT INTERFERONS CAN ENHANCE THE SENSITIVITY OF THE DETECTION OF SERUM TAG-72 AND CEA IN PATIENTS DIAGNOSED WITH ADENOCARCINOMA (1992) (0)
- Biological and Clinical Effects of Intravenous Tumor Necrosis Factor-« Administered Three Times Weekly1 (2006) (0)
- Epigenetic regulation of IFN-α2b activity in multiple myeloma by a non-hydroxamic acid HDAC inhibitor (A-423378) (2008) (0)
- Viruses and breast cancer: implications of mouse and human studies. (1974) (0)
- Mechanisms of Antitumor Action (2003) (0)
- Selective Association of High Density Lipoprotein with Interferon Beta Serine (1987) (0)
- Methylthioadenosine phosphorylase (MTAP) gene deletions are frequent in chondrosarcomas (2005) (0)
- Progress in management of malignant melanoma. (1987) (0)
- Diethyldithiocarbamate (DDC)-mediated blockade of natural killer (NK) cell activity: Relationship to interferon (IFN) effects (1982) (0)
- MODULATION OF IFN RESPONSES IN EMBRYONAL CARCINOMA CELLS BY RETINOIC ACID (1993) (0)
- INCREASING EFFECTS OF INTERFERONS(IFNs)-a ANI IFN-β THROUGH SIGNAL TRANSDUCTION (1999) (0)
- Histologic typing and grading of advanced adult soft tissue sarcomas (clinico-pathologic analysis of 274 cases): An eastern cooperative oncology group (ECOG) experience (1990) (0)
- Circulating tumor cells enrichment and characterization in ALK-translocation positive lung cancer. (2014) (0)
- AugmentedAntiproliferativeEffects of Interferonsat Elevated Temperaturesagainst HumanBladderCarcinomaCell Lines 1 (2006) (0)
- New Therapeutic Directions in Sarcomas: Biologic and Cytotoxic Modalities (1988) (0)
- Interferons α and β in cancer: therapeutic opportunities from new insights (2019) (0)
- SWOG0345: Prospective phase II trial of imatinib in dermatofibrosarcoma protuberans (DFSP) (2008) (0)
- Antitumor and Antimetastatic Activity of Interleukin-10 in Mammary Cancer (1995) (0)
- Role of interferon-α and -β in polyriboinosinic-polyribocytidylic acid-mediated augmentation of natural killer and killer cell cytotoxicity (1981) (0)
- ISIR announcement: Minutes of the ISIR Board of Directors meeting San Francisco, California November 14, 1990 (1991) (0)
- Abstract 1184: The effect of dual VEGF/VEGFR inhibition on angiogenic signaling pathways. (2013) (0)
- Modulation of Immune Effector and Regulator Cells by Sunitinib: Potential for Combination Therapy in Renal Cell Carcinoma Patients (2012) (0)
- in Synergy with IFNs Anticancer Activity of Sodium Stibogluconate (2002) (0)
- Effects of levamisole on monocyte chemotaxis in colorectal carcinoma (1981) (0)
- 508 Effects of interferon on β2 microglobulin, tryptophan, 2 - 5A synthetase and indolinate dioxygenase in early HIV infection (1991) (0)
- Schedule-dependent Variations in the Response of Murine P388 Leukemia to Cyclophosphamide in Combination with Interferons-«//?1 (2006) (0)
- Growth related variation of iodine 125 interferon beta ser binding to human renal and bladder carcinoma cells (1986) (0)
- Molecules: Their Induction, Receptors, and Gene Regulation (2003) (0)
- Effects of interferons on angiotensin induced by bladder carcinoma (BC) (1984) (0)
- Antisense therapy for melanoma (2001) (0)
- AugmentedAntiproliferativeEffects of Interferonsat Elevated Temperaturesagainst (2006) (0)
- Cancer therapy with combinations of biological response modifiers and cytotoxics: an update. (1990) (0)
- PS1-22 Regulation of IFN-α 2 signaling by SHP-1 inhibitor sodium stibogluconate for peripheral immune cell activation ex vivo and in melanoma patients (2010) (0)
- PHARMACODYNAMICS OF GENE MODULATION IN HUMANS AFTER SINGLE AND MULTIPLE DOSES OF INTERFERON (IFN) β (1992) (0)
- Interferons: in pursuit of the promise. (1983) (0)
- 197 The antiapoptotic protein G1P3 (ISG 6-16) in survival signaling in breast carcinoma: Cytokine and endocrine cross talk (2008) (0)
- Molecular Cancer apeutics linical Development sine Phosphatase Inhibitor-3 Sensitizes Melanoma and Ther on Cancer to Biotherapeutics and Chemotherapeutics (2010) (0)
- A phase I trial of VB-111, a tissue- and condition-specific dual action vascular disruptive and antiangiogenic agent, for treatment of patients with advanced metastatic cancer. (2011) (0)
- Antiproliferative effects of poly I: poly C (pI:pC) and amphotericin B methyl ester (AmBME) for human cells (1979) (0)
- AugmentedAntiproliferativeEffects of Interferonsat Elevated Temperaturesagainst HumanBladderCarcinomaCell Lines (2006) (0)
- Abstract 868: Oral SHP-1 inhibitor TPI-1a4 increases TILs in melanoma tumors and interacts positively with CTLA4 antibody for melanoma cure in mice (2012) (0)
- Biotechnology: its impact on medicine and oncology. (1991) (0)
- Microsoft Word-BB Notch1 MT1 paper-JBC-revised.docx (2014) (0)
- Abstract 1684: Inflammatory signaling genes as predictive markers of vorinostat sensitivity in multiple myeloma (2010) (0)
- Effects of 5-aza-deoxycytidine (5-AZA-dC) and histone deacetylase (HDAC) inhibitors on proliferation and gene expression in small cell lung cancer cells (2008) (0)
- A Phase I evaluation of IFN α-1b in solid tumors, lymphoma or myeloma. (2004) (0)
- Ligand-Induced Apoptosis Melanoma Cells to TRAIL / Apo 2 Pretreatment Sensitizes (2002) (0)
- Activation of human peripheral blood immune cells in vitro by sodium stibogluconate (SSG) and SSG/IL-2 combination. (2006) (0)
- Circulating Tumor Cells (CTCs) in Advanced Lung Cancer: Prognostic Impact of Quantification and Morphology by 2 Separate Techniques (2014) (0)
- AN INTERFERON (IFN)-INDUCED 15-kDa PROTEIN ENHANCES THE PROLIFERATION OF LYMPHOCYTES IN VITRO (1993) (0)
- Adult sarcomas: a missed opportunity for sustained cooperative group translational and clinical research. (2007) (0)
- Re-expression of pro-apoptotic genes through reversal of epigenetic silencing to overcome absolute resistance of human melanoma cells to interferons (IFNs), TRAIL, or cisplatin (2006) (0)
- Biological and Clinical Effects of the Combination of ß-and 7-Interferons Administered as a 5-Day Continuous Infusion1 (2006) (0)
- Mechanistic Studies ofPolyene Enhancement ofInterferon Production byPolyriboinosinic -Polyribocytidyl ic Acid (1978) (0)
- Imidazoquinolinamine Inhibition of Murine Tumor Growth by an Interferon-inducing Updated Version (2006) (0)
- Antitumor Effects in Humans (2003) (0)
- Comparison of microfilter-based capture to CellSearch in detection of circulating tumor cells (CTCs) in patients with metastatic castration-resistant prostate cancer (mCRPCa). (2014) (0)
- Peroxo-citrate-vanadium(V) complex: protein tyrosine phosphatase inhibitory activity and anticancer potential (2005) (0)
- Induction of TRAIL and XAF-1 and inhibition of p-Akt and c-Kit expression by interferons (IFNs) is associated with apoptosis in GIST cells. (2004) (0)
- Interferons for human neoplastic and viral diseases. (1980) (0)
- Interferon (IFN)-stimulated genes (ISGs) as a resistance mechanism in cancer cell death (2009) (0)
- Toremifene and IFN-??2b synergistically inhibit growth of human breast carcinoma (MCF-7 and MDA-MB-231) and melanoma (A375) in vitro (1996) (0)
- Augmentation in the infectivity of SV40 virus DNA by amphotericin B methyl ester (2005) (0)
- Interferons: Preclinical and Clinical Studies in Melanoma (2002) (0)
- Abstract 1454: Evaluation of negative selection strategy for enrichment of circulating melanoma cells (CMCs) from patients with metastatic melanoma. (2013) (0)
- 486 POSTER Combined targeting of DNA repair and AKT survival pathways enhance temozolomide therapeutic activity in melanoma (2008) (0)
- Cytokines and monoclonal antibodies: an introduction of their current and future applications to cancer and other diseases. (1992) (0)
- Effect of IFN-beta and IFN-gamma on Ia and 2'-5' A synthetase expression in HL-60 and U937 cells (1985) (0)
- Symposium on breast cancer. Introduction. (1974) (0)
- Therapie combinee utilisant la reduction de l'expression et/ou de l'activite de la methyltransferase d'adn et l'interferon (2006) (0)
- 336 POSTER Targeting MKP1 with novel chemical inhibitors sensitizes melanoma and colon cancer cells to chemotherapeutics in vitro and in vivo (2008) (0)
- RapidDetection andIdentification ofJCVirus andBK Virus inHumanUrine byUsingImmunofluorescence Microscopy (1980) (0)
- HDAC Inhibitor Plus Doxorubicin Combinations Reverse Apoptosis Resistance in Myeloma Cells by Triggering Cathepsin-Mediated Bax Activation (2008) (0)
- The association of toxicities and outcomes with circulating endothelial cells (CEC) in non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (Bev). (2013) (0)
- Abstract 188: Interferon stimulated gene expression as a potential resistance mechanism in DNA damage from epigenetic inhibitors (2010) (0)
- Effects of interferons (IFN) and IFN-inducers on serotonin-initiated increase in vascular permeability (1985) (0)
- Ludgwig gross, oncogenic viruses, Second Edition, Pergamon Press, Oxford, 1970 (1972) (0)
- Abstract 1560: VE-PTP inhibitor AKB-9778 mitigates IL-2-induced VLS and interacts positively with IL-2 against melanoma and renal cancer tumors in mice (2010) (0)
- Tolerated Oral Agents Preclinical Anti-Tumor Activities as Phosphatase Inhibitor-1 and Analogs with Novel SHP-1 Inhibitors Tyrosine (2010) (0)
- The effect of interferon gamma (IFNγ) on HLA-DR, beta-2-microglobulin (β2M), and tumor associated antigen (TAA) expression on bladder tumor cells (1985) (0)
- Phase I expansion study of sunitinib and bevacizumab in patients with advanced solid malignancies. (2013) (0)
- Subsets of natural killer and killer cells defined by buoyant-density and response to polyriboinosinic: polyribocytidylic acid (1981) (0)
- 5-aza-deoxycytidine (5-Aza-dC) restores interferon-stimulated gene (ISG) expression and IFN-induced anti-proliferative effects in melanoma cells (2008) (0)
- Erratum to Inhibitory effects of cytokines on vascular endothelial cells: Synergistic interactions among interferon-γ, tumor necrosis factor-α, and interleukin-1 (July 1992, 12(1), 13-18) (1992) (0)
- Increasing interferons (IFNs) effectiveness through augmentation of gene expression (1997) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ernest C. Borden?
Ernest C. Borden is affiliated with the following schools:
